119 related articles for article (PubMed ID: 3116281)
1. Hormonal effects of cessation of estrogen treatment for prostatic carcinoma.
Tomić R; Bergman B
J Urol; 1987 Oct; 138(4):801-3. PubMed ID: 3116281
[TBL] [Abstract][Full Text] [Related]
2. Effect of orchidectomy performed after cessation of estrogen therapy on serum testosterone concentrations in patients with prostatic carcinoma.
Tomić R; Damber JE
Urol Int; 1987; 42(6):441-4. PubMed ID: 3129850
[TBL] [Abstract][Full Text] [Related]
3. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
4. Pituitary function after orchiectomy in patients with or without earlier estrogen treatment for prostatic carcinoma.
Tomić R
J Endocrinol Invest; 1987 Oct; 10(5):479-82. PubMed ID: 3123547
[TBL] [Abstract][Full Text] [Related]
5. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma.
Daehlin L
Scand J Urol Nephrol Suppl; 1985; 91():1-44. PubMed ID: 3868029
[TBL] [Abstract][Full Text] [Related]
6. Endocrine effects of oestrogen withdrawal in long-term treated patients with prostatic adenocarcinoma.
Tomić R; Damber JE; Bergman B
Eur Urol; 1988; 14(1):6-8. PubMed ID: 3342807
[TBL] [Abstract][Full Text] [Related]
7. Prostatic carcinoma: plasma kinetics and intraprostatic metabolism of testosterone in low-dose estrogen-treated patients in vivo.
Jacobi GH; Sinterhauf K; Altwein JE
Urology; 1978 Sep; 12(3):359-64. PubMed ID: 706029
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rhode W
Z Urol Nephrol; 1987 Mar; 80(3):125-33. PubMed ID: 3604471
[TBL] [Abstract][Full Text] [Related]
9. [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
Z Urol Nephrol; 1987 Dec; 80(12):665-8. PubMed ID: 3126615
[TBL] [Abstract][Full Text] [Related]
10. Testicular endocrine function after withdrawal of oestrogen treatment in patients with carcinoma of the prostate.
Tomić R; Bergman B; Damber JE
Br J Urol; 1983 Feb; 55(1):42-7. PubMed ID: 6402048
[TBL] [Abstract][Full Text] [Related]
11. Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin.
Tomić R; Bergman B; Damber JE; Littbrand B; Löfroth PO
J Urol; 1983 Aug; 130(2):287-9. PubMed ID: 6410084
[TBL] [Abstract][Full Text] [Related]
12. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.
Brennemann W; Stoffel-Wagner B; Helmers A; Mezger J; Jäger N; Klingmüller D
J Urol; 1997 Sep; 158(3 Pt 1):844-50. PubMed ID: 9258096
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
[TBL] [Abstract][Full Text] [Related]
14. Some effects of treatment with ethinyl oestradiol with or without polyoestradiol phosphate in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol; 1986; 20(3):193-6. PubMed ID: 3097813
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous 17 beta-estradiol in treatment of cancer of prostate.
Steg A; Benoit G
Urology; 1979 Oct; 14(4):373-5. PubMed ID: 227153
[TBL] [Abstract][Full Text] [Related]
16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
17. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
Lin BJ; Chen KK; Chen MT; Chang LS
Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
Jorion JL
J Urol; 1992 Nov; 148(5):1539-40. PubMed ID: 1279215
[No Abstract] [Full Text] [Related]
19. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer.
Petersen PM; Skakkebaek NE; Vistisen K; Rørth M; Giwercman A
J Clin Oncol; 1999 Mar; 17(3):941-7. PubMed ID: 10071288
[TBL] [Abstract][Full Text] [Related]
20. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
Carlström K; Stege R
Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
